Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1523518

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment

Provisionally accepted
Liubov A Tashireva Liubov A Tashireva *Irina V Larionova Irina V Larionova Nikita A Ermak Nikita A Ermak Anastasia A Maltseva Anastasia A Maltseva Ekaterina I Livanos Ekaterina I Livanos Anna Yu Kalinchuk Anna Yu Kalinchuk Marina N Stakheyeva Marina N Stakheyeva Larisa A Kolomiets Larisa A Kolomiets
  • Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

The final, formatted version of the article will be published soon.

    Immunotherapy represents a groundbreaking therapeutic approach, based on the immune system's intrinsic capacity to interfere with tumor progression, that opens the horizons in the treatment of endometrial cancer. However, the clinical efficacy of immunotherapy is hampered by the development of resistance in patients. The resistance to immunotherapy is multifactorial mechanism, encompassed genetic and epigenetic alterations in tumor cells modulating immune checkpoint molecules, resulted in escaping immune surveillance. The tumor microenvironment can orchestrate an immunosuppressive milieu, attenuating the immune response and facilitating tumor progression.To overcome immunotherapeutic resistance in endometrial cancer we must bring to light the mechanisms of intricate interplay between neoplastic cells, the host immune system, and the tumor microenvironment. The identification of predictive biomarkers for immunotherapeutic response and the innovative agents capable of reversing resistance pathways must be developed. Our review summarizes accumulated data on the role of cells of the tumor microenvironment and their regulatory molecules in the mechanisms underlying therapeutic effects of immune checkpoint inhibitors, including resistance to therapy. Major question we raise herewhich group of patients is the most favorable to achieve durable immunotherapy response in endometrial cancer?

    Keywords: endometrial cancer, Immunotherapy, immune checkpoint inhibitors, Tumor Microenvironment, predictive biomarkers

    Received: 06 Nov 2024; Accepted: 24 Dec 2024.

    Copyright: © 2024 Tashireva, Larionova, Ermak, Maltseva, Livanos, Kalinchuk, Stakheyeva and Kolomiets. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Liubov A Tashireva, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.